DSpace Repository

Generation of liver tissue-resident memory T cells with novel NKT cell agonists and mRNA vaccines

Show simple item record

dc.rights.license CC BY-NC-SA 4.0
dc.contributor.advisor Painter, Gavin
dc.contributor.advisor Ackerley, David
dc.contributor.advisor Hermans, Ian
dc.contributor.author Ganley, Mitch
dc.date.accessioned 2023-03-28T04:05:04Z
dc.date.available 2023-03-28
dc.date.available 2023-03-28T04:05:04Z
dc.date.copyright 2023-03-28
dc.date.issued 2023-03-28
dc.identifier.uri https://ir.wgtn.ac.nz/handle/123456789/30641
dc.identifier.uri 10.26686/wgtn.25792368
dc.identifier.uri https://openaccess.wgtn.ac.nz/articles/thesis/Generation_of_liver_tissue-resident_memory_T_cells_with_novel_NKT_cell_agonists_and_mRNA_vaccines/25792368
dc.description.abstract mRNA vaccines have become a central part of vaccine research over the last decade due to their application in cancer immunotherapy, and more recently, the rapid response to the SARS-CoV-2 pandemic leading to two clinically approved mRNA vaccines that generate cellular and humoral immunity. These vaccines have saved countless lives and have paved the way for the prevention and treatment of infectious diseases with new mRNA vaccines. One area of ongoing investigation is the longevity and specificity of the adaptive immune response which incorporates both humoral (i.e. antibody) and cellular (T cell) memory. Whilst the focus of the SARS-CoV-2 vaccines was humoral-mediated immunity another emerging field of immunology and vaccine development is the function and generation of tissue-resident memory T(rm) cells. These specialised memory cells reside in tissues awaiting the presence of a pathogen and “raise the alarm” when they encounter the pathogen. This involves the production of inflammatory cytokines that attract other circulating immune cells and have a rapid cytotoxic function that eliminates infected cells. Previous work has shown that the activation of “innate-like” natural killer T (NKT) cells can improve adaptive immune responses, including the production of Trm cells in the liver that can provide sterile protection from malaria sporozoites. This work explored the use of and effect on the adaptive cellular immune system of vaccines comprising NKT cell agonists and mRNA encoding pathogen antigens co-delivered in lipid-delivery vehicles. The inclusion of an NKT cell agonist improved the generation of circulating effector memory CD8+ T(em) cells and the type of ligand affected the magnitude of the priming effector response. Surprisingly, whilst the magnitude of Tem responses generally predicted other memory responses, liver Trm responses were detached from priming responses with regard to specific agonist compounds. In particular, several novel NKT cell agonists, including CI058 generated substantially more liver Trm than the prototypical NKT cell agonist, aGalCer, even though aGalCer induced stronger priming Tem responses. The liver Trm inducing capacity of the novel NKT cell agonists was dependent on modification at the 6’ position of the galactose of a-linked glycolipids. The vaccines developed during this work were able to generate protective liver Trm that could be boosted and protect from Plasmodium sporozoite challenge to model and disease-relevant Plasmodium antigens. Additionally, global research efforts have demonstrated vaccine or infection-acquired immunity (antibody or liver Trm) is impaired by previous red blood cell (RBC) infection by Plasmodium. In contrast, the liver CD8+ Trm cells generated by these NKT cell-adjuvanted mRNA vaccines were unaffected by previous RBC infection. The specific signals from NKT cells that contribute to this improvement in liver Trm formation are unclear, but the response is dependent on both the mRNA vaccine and NKT cell signalling. The response was abrogated in the absence of NKT cells and its magnitude was dependent on a NKT cell phenotype. Modulation of the mRNA component could either impair or improve the overall response and there is synergy between NKT cell and TLR signalling in DC licencing and IL-12 production that positively correlates with liver Trm.
dc.language.iso en_NZ
dc.rights https://www.wgtn.ac.nz/library/about-us/policies-and-strategies/copyright-for-the-researcharchive
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject mRNA vaccines
dc.subject Malaria
dc.subject NKT cells
dc.title Generation of liver tissue-resident memory T cells with novel NKT cell agonists and mRNA vaccines
dc.type text
dc.date.updated 2023-03-28T04:05:03Z
dc.rights.holder All rights, except those explicitly waived, are held by the Author
vuwschema.contributor.unit Ferrier Research Institute
vuwschema.contributor.unit Malaghan Institute for Medical Research
vuwschema.subject.anzsrcfor 110704 Cellular Immunology
vuwschema.subject.anzsrcfor 110707 Innate Immunity
vuwschema.subject.anzsrcseo 929999 Health not elsewhere classified
vuwschema.subject.anzsrctoa 4 Experimental Development
vuwschema.type.vuw Awarded Doctoral Thesis
thesis.degree.discipline Biotechnology
thesis.degree.grantor Te Herenga Waka—Victoria University of Wellington
thesis.degree.level Doctoral
thesis.degree.name Doctor of Philosophy
dc.subject.course BTEC695
vuwschema.subject.anzsrcforV2 320404 Cellular immunology
vuwschema.subject.anzsrcforV2 320407 Innate immunity
vuwschema.subject.anzsrcseoV2 209999 Other health not elsewhere classified
vuwschema.subject.anzsrctoaV2 4 Experimental research

Files in this item

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-SA 4.0 Except where otherwise noted, this item's license is described as CC BY-NC-SA 4.0

Search DSpace


My Account